Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04136366 · ClinicalTrials.gov registry record · Phase 3
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
A Phase 3 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
NCT04136366 is a Phase 3 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 106 participants.
The verdict
NCT04136366, a Phase 3 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
Study Summary
The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.
Interventions
- DRUG ADX-2191 (intravitreal methotrexate 0.8%)
- OTHER Standard surgical care procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2022-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04136366
The ClinicalTrials.gov registry entry for NCT04136366 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ADX-2191 (intravitreal methotrexate 0.8%) is the first listed.
NCT04136366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04136366 about?
NCT04136366 is a clinical study titled "The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy". The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.
What is the current status of trial NCT04136366?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2019-11-15. Estimated completion is 2022-06-14.
What interventions are being tested in trial NCT04136366?
The interventions under investigation include: ADX-2191 (intravitreal methotrexate 0.8%) (DRUG), Standard surgical care procedure (OTHER).
Who is sponsoring clinical trial NCT04136366?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.